PD-L1 and VEGF

Programmed death-ligand 1 (PD-L1) is a type I transmembrane protein belonging to the B7 family and is a critical immune checkpoint ligand that binds programmed death 1 (PD-1) on T cells and inhibits T-cell-mediated immune responses. This interaction allows tumors to evade immune surveillance, and blockade of PD-L1 with monoclonal antibodies enhances anti-tumor immunity. Vascular endothelial growth factor (VEGF) is a secreted glycoprotein primarily involved in the stimulation of angiogenesis and increased vascular permeability. It is a key regulator of blood vessel formation in normal and pathological conditions, including cancer, where it promotes tumor growth by supplying nutrients and oxygen via new blood vessel formation. Therapeutic inhibition of VEGF signaling blocks angiogenesis and can suppress tumor progression. Targeting both PD-L1 and VEGF simultaneously is of high interest in oncology, particularly in solid tumors, due to a mechanistic synergism: anti-PD-L1 agents restore immune responses while anti-VEGF agents inhibit angiogenesis and can also help overcome immunosuppressive effects within the tumor microenvironment. Several bispecific antibodies and combination regimens are under clinical and preclinical investigation for these purposes. In summary, 'PD-L1 and VEGF' commonly refers to dual targeting of these two distinct but highly validated therapeutic targets in cancer. For structured information, they should be captured as separate canonical entities—one for PD-L1 and one for VEGF—each with its own specific molecular and clinical properties.

Other names

CD274B7 homolog 1 (B7-H1)Vascular permeability factor (VPF)vaculotropinVEGFA

Immune checkpoint blockade via PD-L1 targeting restores T-cell activation and anti-tumor immunity by blocking PD-L1/PD-1 interaction. Concurrently, VEGF targeting inhibits angiogenesis, reducing tumor vascular supply and being anti-proliferative in the context of tumor blood vessel formation. Dual targeting aims for synergistic anti-tumor effects, combining immune activation with inhibition of tumor angiogenesis and overcoming immunosuppressive effects within the tumor microenvironment.